Investment Type: Venture Capital
Mentions in press and media 12
| Date | Title | Description |
| 22.06.2026 | Syntax Bio Expands Series A to $14.4M | Syntax Bio, a Chicago, IL-based synthetic biology company programming new cell therapies, expanded its Series A to $14.4M. The expanded round saw participation from Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Vent... |
| 15.12.2016 | Oncorus Announces Additional Series A Financing Support From Astellas Venture Management | Oncorus®, Inc., a new immuno-oncology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiform... |
| 20.05.2013 | eFFECTOR Therapeutics Completes $45M Series A Financing | eFFECTOR Therapeutics, a San Diego, CA-based newly formed biopharmaceutical company, completed a $45m Series A financing. Backers included U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage... |
| 20.05.2013 | eFFECTOR Therapeutics Raises $45 Million in Series A Financing | eFFECTOR Therapeutics Raises $45 Million in Series A Financing Company to Focus on Small Molecule Selective Regulators of Protein Synthesis for Cancer San Diego, CA – May 20, 2013 – eFFECTOR Therapeutics, a newly established biopharmaceutic... |
| 26.02.2013 | DecImmune Therapeutics Secures $2.25M | CAMBRIDGE, MA, DecImmune Therapeutics announced today that it has completed a $2.25 million equity financing. >> Click here for more funding data on DecImmune Therapeutics >> To export DecImmune Therapeutics funding data to ... |
| 26.02.2013 | DecImmune Therapeutics Completes $2.25M Equity Financing | DecImmune Therapeutics, a Cambridge, MA-based company that develops novel peptides and antibodies for acute, tissue damaging inflammation in myocardial infarction, burns, and other conditions involving vascular injury and reperfusion, compl... |
| 21.08.2012 | Type 2 diabetes drug with goal of 24/7 glycemic control begins Phase 2b trial | The biotechnology firm raised $48.4 million earlier this year in its third tranche for its series B financing round led by New Enterprise Associates with participation by Hatteras Venture Partners, Johnson & Johnson Development Corp., A... |
| 15.11.2011 | Hyperglycemia drug gets positive results in clinical trial | GLP-1 analogues that have been approved by the U.S. Food and Drug Administration need to be given at least once a day, said Lynne Georgopoulos, senior vice president of clinical development. “Our intent was to develop a long-acting drug tha... |
| 11.10.2011 | Cleave Biosciences Raises $42M in Series A Financing | Cleave Biosciences, a Burlingame, California-based newly established biopharmaceutical company discovering and developing novel therapies for cancer, has raised $42m in Series A financing. Investors include U.S. Venture Partners, 5AM Ventur... |
| 07.01.2009 | Intradigm closes $21.4M for cancer therapeutics | Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer. ... |
Show more